Pharmaceutical giants urge FDA to use blockchain to track prescription drugs

After completing a pilot program with the US Food and Drug Administration (FDA), MediLedger, a drug traceability blockchain alliance, published a report advocating the use of blockchain technology to track and trace prescription drugs. The report states that the lack of a “central point of data sharing” will cause the U.S. pharmaceutical supply to lag behind international competitors, as companies “have difficulty in maintaining accurate and complete data sharing among various partners, systems, and technology formats”. The document warns that in the event of a major public health crisis, stakeholders and agents will find it difficult to locate and isolate suspicious products in a timely manner and continue to put patients' lives at risk, and blockchain can avoid these major risks. The MediLedger report states that the data privacy requirements of the pharmaceutical industry can be maintained by maintaining zero-knowledge proof technology. It is reported that members of the alliance include pharmaceutical manufacturers Pfizer, Eli Lilly, GlaxoSmithKline, Amgen, Novartis and Sanofi, pharmaceutical wholesale or retail companies M source Bergen, Walgreens and Wal-Mart, and the distribution company FedEx.